Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARQ 197 plus Erlotinib in EGFR+ NSCLC
NCT01580735Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- May 2012
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tivantinib in non-small cell lung cancer (NSCLC), sponsored by Kyowa Kirin. Started May 2012; status: completed.
02
Drugs
tivantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01580735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01580735.